##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
 FORM 10-QSB/A Quarterly Report Under section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended December 31, 2003 Commission File No. 000-20989 UROPLASTY, INC.  Minnesota, U.S.A.
(State or other jurisdiction of
incorporation or organization)
    
    41-1719250
(I.R.S. Employer
Identification No.)
 2718 Summer Street NE
Minneapolis, Minnesota 55413-2820
(Address of principal executive offices) (612) 378-1180
(Issuers telephone number, including area code) Securities registered under Section 12(g) of the Exchange Act: Common Stock, $.01 par value (Title of class) Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the
past 12 months (or for such shorter period that the Company was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days. YES
[X]          NO
[   ] The aggregate market value of the voting stock held by non-affiliates computed by reference to the price
at which the
stock was sold or the average bid and asked prices of such stock as of February 1, 2004 was $16,696,512. The number of shares outstanding of the issuers only class of common stock on February 1, 2004 was 4,565,004. Transitional Small Business Disclosure Format: YES
[   ]          NO [X] Uroplasty is filing this Form 10-QSB/A as a result of matters discussed in the
Notes to the Interim Consolidated Financial Statements  Restatements to the
unaudited consolidated financial statements included in this Form 10-QSB/A.    Page 1




---



TABLE OF CONTENTS  PART I. FINANCIAL INFORMATIONITEM 1. FINANCIAL STATEMENTSCONSOLIDATED BALANCE SHEETSCONSOLIDATED STATEMENTS OF OPERATIONSCONSOLIDATED STATEMENTS OF CASH FLOWSNOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTSITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONITEM 3. CONTROLS AND PROCEDURESPART II. OTHER INFORMATIONITEM 2. CHANGES IN SECURITIESITEM 6. EXHIBITS AND REPORTS ON FORM 8-KSIGNATURESCertifications of CEO and CFO Pursuant to Section 302Certifications of CEO and CFO Pursuant to Section 906    Table of Contents  
 PART I. FINANCIAL INFORMATION 
 ITEM 1. FINANCIAL
STATEMENTS UROPLASTY, INC. AND SUBSIDIARIES 
 CONSOLIDATED BALANCE SHEETS December 31, 2003
    
    March 31, 2003(unaudited)(restated)
    
    (restated)AssetsCurrent assets:Cash and cash equivalents
    
    $
    2,613,903
    
    
    $
    3,375,981Accounts receivable, net
    
    
    1,021,959
    
    
    
    969,556Inventories
    
    
    499,288
    
    
    
    455,114Other
    
    
    196,374
    
    
    
    188,192Total current assets
    
    
    4,331,524
    
    
    
    4,988,843Property, plant, and equipment, net
    
    
    1,075,488
    
    
    
    833,234Intangible assets, net
    
    
    49,607
    
    
    
    48,214Deferred tax assets
    
    
    120,936
    
    
    
    94,159Total assets
    
    $
    5,577,555
    
    
    $
    5,964,450
 See accompanying notes to consolidated financial statements. Page 2




---



##### Table of Contents



UROPLASTY, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS December 31, 2003
    
    March 31, 2003(unaudited)(restated)
    
    (restated)Liabilities and Shareholders EquityCurrent liabilities:Accounts payable
    
    $
    131,813
    
    
    $
    199,673Income tax payable
    
    
    226,365
    
    
    
    Accrued liabilities
    
    
    315,134
    
    
    
    381,653Current maturities  long-term debt
    
    
    43,350
    
    
    
    37,502Total current liabilities
    
    
    716,662
    
    
    
    618,828Long-term debt  less current maturities
    
    
    502,454
    
    
    
    462,787Accrued pension liability
    
    
    278,988
    
    
    
    241,208Total liabilities
    
    
    1,498,104
    
    
    
    1,322,823Shareholders equity:Common stock $.01 par value; 20,000,000
shares authorized, 4,560,337 and
4,488,971 shares issued and
outstanding at December 31, 2003 and
March 31, 2003, respectively
    
    
    45,603
    
    
    
    44,890Additional paid-in capital
    
    
    9,066,198
    
    
    
    8,457,901Accumulated deficit
    
    
    (4,672,673
    )
    
    
    (3,245,329
    )Vendor deposit
    
    
    
    
    
    
    (112,000
    )Deferred compensation
    
    
    (168,723
    )
    
    
    Accumulated other comprehensive loss
    
    
    (190,954
    )
    
    
    (503,835
    )Total shareholders equity
    
    
    4,079,451
    
    
    
    4,641,627Total liabilities and shareholders equity
    
    $
    5,577,555
    
    
    $
    5,964,450
 See accompanying notes to consolidated financial statements. Page 3




---



##### Table of Contents



UROPLASTY, INC. AND SUBSIDIARIES 
 CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited) Three Months Ended
    
    Nine Months EndedDecember 31,
    
    December 31,2003
    
    2002
    
    2003
    
    2002(restated)
    
    
    
    
    
    (restated)Net sales
    
    $
    1,447,671
    
    
    
    1,264,742
    
    
    $
    3,982,333
    
    
    
    3,862,716Cost of goods sold
    
    
    404,130
    
    
    
    330,015
    
    
    
    1,107,105
    
    
    
    1,105,018Gross profit
    
    
    1,043,541
    
    
    
    934,727
    
    
    
    2,875,228
    
    
    
    2,757,698Operating expensesGeneral and administrative
    
    
    493,905
    
    
    
    312,003
    
    
    
    1,450,447
    
    
    
    884,131Research and development
    
    
    454,349
    
    
    
    538,295
    
    
    
    1,336,313
    
    
    
    1,539,503Selling and marketing
    
    
    487,619
    
    
    
    251,051
    
    
    
    1,286,922
    
    
    
    764,8781,435,873
    
    
    
    1,101,349
    
    
    
    4,073,682
    
    
    
    3,188,512Operating loss
    
    
    (392,332
    )
    
    
    (166,622
    )
    
    
    (1,198,454
    )
    
    
    (430,814
    )Other income (expense)Interest income
    
    
    6,715
    
    
    
    12,482
    
    
    
    23,832
    
    
    
    35,075Interest expense
    
    
    (5,291
    )
    
    
    (5,805
    )
    
    
    (16,539
    )
    
    
    (18,144
    )Foreign currency exchange gain
    
    
    11,697
    
    
    
    146,024
    
    
    
    5,126
    
    
    
    553,357Settlement
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    180,000Other
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (157
    )13,121
    
    
    
    152,701
    
    
    
    12,419
    
    
    
    750,131Income (loss) before income taxes
    
    
    (379,211
    )
    
    
    (13,921
    )
    
    
    (1,186,035
    )
    
    
    319,317Income tax expense
    
    
    120,914
    
    
    
    
    
    
    
    241,309
    
    
    
    Net income (loss)
    
    $
    (500,125
    )
    
    
    (13,921
    )
    
    $
    (1,427,344
    )
    
    
    319,317Basic income (loss) per common share
    
    $
    (0.11
    )
    
    
    (0.00
    )
    
    $
    (0.32
    )
    
    
    0.09Diluted income (loss) per common share
    
    $
    (0.11
    )
    
    
    (0.00
    )
    
    $
    (0.32
    )
    
    
    0.09Weighted average common shares
outstanding:Basic
    
    
    4,530,657
    
    
    
    4,467,547
    
    
    
    4,500,677
    
    
    
    3,564,155Diluted
    
    
    4,530,657
    
    
    
    4,467,547
    
    
    
    4,500,677
    
    
    
    3,587,996
 See accompanying notes to consolidated financial statements. Page 4




---



##### Table of Contents



UROPLASTY, INC. AND SUBSIDIARIES 
 CONSOLIDATED STATEMENTS OF CASH FLOWS Nine Months EndedDecember 31,2003
    
    2002(unaudited)
    
    (unaudited)(restated)Cash flows from operating activities:Net income (loss)
    
    $
    (1,427,344
    )
    
    
    319,317Adjustments to reconcile net income (loss) to net cash
provided by (used in) operations:Depreciation and amortization
    
    
    118,706
    
    
    
    149,483Stock-based consulting expense
    
    
    304,290
    
    
    
    1,508Changes in operating assets and liabilities:Accounts receivable
    
    
    84,563
    
    
    
    44,905Inventories
    
    
    88,411
    
    
    
    53,383Other current assets
    
    
    7,710
    
    
    
    (84,968
    )Deferred tax assets
    
    
    (15,164
    )
    
    
    Accounts payable
    
    
    (49,119
    )
    
    
    62,320Accrued liabilities
    
    
    118,320
    
    
    
    (63,457
    )Accrued pension liability
    
    
    11,106
    
    
    
    Additional pension liability
    
    
    (2,222
    )
    
    
    Net cash provided by (used in) operating activities
    
    
    (760,743
    )
    
    
    482,491Cash flows from investing activities:Payments for property, plant and equipment
    
    
    (63,669
    )
    
    
    (44,757
    )Payments for intangible assets
    
    
    (18,773
    )
    
    
    (675
    )Net cash used in investing activities
    
    
    (82,442
    )
    
    
    (45,432
    )Cash flows from financing activities:Repayment of long-term debt
    
    
    (29,383
    )
    
    
    (37,674
    )Net proceeds from issuance of stock
    
    
    49,917
    
    
    
    2,265,316Net cash provided by financing activities
    
    
    20,534
    
    
    
    2,227,642Effect of exchange rates on cash and cash equivalents
    
    
    60,573
    
    
    
    (146,646
    )Net increase (decrease) in cash and cash equivalents
    
    
    (762,078
    )
    
    
    2,518,055Cash and cash equivalents at beginning of period
    
    
    3,375,981
    
    
    
    1,046,121Cash and cash equivalents at end of period
    
    $
    2,613,903
    
    
    
    3,564,176Supplemental disclosure of cash flow information:Cash paid during the period for interest
    
    $
    17,723
    
    
    $
    19,503Cash paid during the period for income taxes
    
    
    38,808
    
    
    
    Shares issued for 401(k) plan profit sharing contribution
    
    
    28,080
    
    
    
    27,270Restricted shares issued for mold purchase
    
    
    
    
    
    
    24,000Vesting of restricted shares for mold purchase
    
    
    170,000
    
    
    
    
 See accompanying notes to consolidated financial statements. Page 5




---



##### Table of Contents



UROPLASTY, INC. AND SUBSIDIARIES 
 NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS  1. Basis of Presentation The consolidated financial statements included in this Form 10-QSB have been prepared by Uroplasty, Inc. (Uroplasty or the Company), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to such rules and regulations. The consolidated results of operations for any interim period are not necessarily indicative of results for a full year. These consolidated statements should be read in conjunction with the consolidated financial statements and related notes included in the Companys Annual Report on Form 10-KSB for the year ended March 31, 2003. The consolidated financial statements presented herein as of December 31, 2003 and for the three and nine-months periods ended December 31, 2003 and 2002 reflect, in the opinion of management, all material adjustments consisting only of normal recurring adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows for the interim periods. The Company has identified certain of its accounting policies that it considers particularly important for the portrayal of the Companys results of operations and financial position and which may require the application of a higher level of judgment by the Companys management, and as a result are subject to an inherent level of uncertainty. These are characterized as critical accounting policies and address revenue recognition, inventories, foreign currency translation and transactions, and impairment of long-lived assets, each more fully described in the Companys Annual Report on Form 10-KSB for the year ended March 31, 2003. Based upon the Companys review, management has determined that these policies remain its most critical accounting policies for the three and nine-months periods ended December 31, 2003, and has made no changes to these policies during fiscal 2004. 2. Nature of Business The Company is currently selling its products outside of the United States and is undertaking FDA investigational clinical trials in the United States and Canada. Based on the Companys current plans, it is anticipated the Company will launch its products in the U.S. after obtaining FDA approval. Completing clinical trials and obtaining FDA approval is a costly and time-consuming process. As a result of the $2.4 million gross proceeds of a Rights Offering completed July 2002, management believes current resources and the funds generated from sale of the Companys products outside the U.S. will be adequate to meet the Companys cash flow needs, including R&D activities, associated with existing products and markets through fiscal 2005. Ultimately, the Company will need to achieve profitability and positive cash flows from operations or obtain additional debt or equity financing to fund its operations. 3. Restatements During the fiscal 2004 year end close process, the Company determined that its pension plan, covering 18 employees in The Netherlands, had historically been reported as a defined contribution plan, but should have been reported as a defined benefit plan. The Company pays premiums to an insurance company to fund annuities for these employees. However, the Company is responsible for funding additional annuities based on continued service and future salary increases. Contemporaneously, the Company also discovered an error in how it recorded the effect of exchange rates on cash and cash equivalents in the statement of cash flows. Historically, the Company prepared the statement of cash flows on a consolidated basis using year-end exchange rates. Instead, the Company should have prepared the statement of cash flows on an entity basis using average exchange rates in accordance with paragraph 25 of FAS 95. In this Form 10-QSB/A, the Company has restated its balance sheet as of December 31, 2003 and as of March 31, 2003, consolidated results of operations for the three and nine months ended December 31, 2003, consolidated statement of cash flows for the nine months ended December 31, 2003 and related footnote disclosures for the impact of accounting for the pension plan as a defined benefit plan and for the correction of the effect of exchange rates on cash and cash equivalents as follows: Page 6




---



##### Table of Contents



December 31, 2003
    
    March 31, 2003As Previously
    
    
    
    
    
    As PreviouslyReported
    
    As Restated
    
    Reported
    
    As RestatedBALANCE SHEET DATA:Other current assets
    
    $
    296,677
    
    
    $
    196,374
    
    
    $
    188,192
    
    
    $
    188,192Deferred tax assets
    
    
    
    
    
    
    120,936
    
    
    
    
    
    
    
    94,159Total assets
    
    
    5,556,922
    
    
    
    5,577,555
    
    
    
    5,870,291
    
    
    
    5,964,450Accrued current liabilities
    
    
    317,986
    
    
    
    315,134
    
    
    
    349,937
    
    
    
    381,653Accrued pension liability
    
    
    
    
    
    
    278,988
    
    
    
    
    
    
    
    241,208Accumulated deficit
    
    
    (4,550,320
    )
    
    
    (4,672,673
    )
    
    
    (3,163,156
    )
    
    
    (3,245,329
    )Accumulated other comprehensive loss
    
    
    (57,804
    )
    
    
    (190,954
    )
    
    
    (407,243
    )
    
    
    (503,835
    )Total shareholdersequity
    
    
    4,334,954
    
    
    
    4,079,451
    
    
    
    4,820,392
    
    
    
    4,641,627Total liabilities and shareholdersequity
    
    $
    5,556,922
    
    
    $
    5,577,555
    
    
    $
    5,870,291
    
    
    $
    5,964,450
 Three Months Ended
    
    Nine Months EndedDecember 31, 2003
    
    December 31, 2003As Previously
    
    
    
    
    
    As PreviouslyReported
    
    As Restated
    
    Reported
    
    As RestatedSTATEMENT OF OPERATIONS DATA:Cost of goods sold
    
    $
    421,187
    
    
    $
    404,130
    
    
    $
    1,100,960
    
    
    $
    1,107,105Operating expensesGeneral and administrative
    
    
    510,218
    
    
    
    493,905
    
    
    
    1,432,263
    
    
    
    1,450,447Research and development
    
    
    471,406
    
    
    
    454,349
    
    
    
    1,330,169
    
    
    
    1,336,313Selling and marketing
    
    
    503,931
    
    
    
    487,619
    
    
    
    1,268,735
    
    
    
    1,286,922Operating loss
    
    
    (459,071
    )
    
    
    (392,332
    )
    
    
    (1,149,794
    )
    
    
    (1,198,454
    )Loss before income taxes
    
    
    (445,950
    )
    
    
    (379,211
    )
    
    
    (1,137,375
    )
    
    
    (1,186,035
    )Income tax expense
    
    
    97,375
    
    
    
    120,914
    
    
    
    249,789
    
    
    
    241,309Net loss
    
    $
    (543,325
    )
    
    $
    (500,125
    )
    
    $
    (1,387,164
    )
    
    $
    (1,427,344
    )Net loss per common shareBasic
    
    $
    (0.12
    )
    
    $
    (0.11
    )
    
    $
    (0.31
    )
    
    $
    (0.32
    )Diluted
    
    $
    (0.12
    )
    
    $
    (0.11
    )
    
    $
    (0.31
    )
    
    $
    (0.32
    )CASH FLOW DATA:Net cash used in operating activities
    
    
    
    
    
    
    
    
    
    $
    (1,014,081
    )
    
    $
    (760,743
    )Net cash used in investing activities
    
    
    
    
    
    
    
    
    
    
    (82,717
    )
    
    
    (82,442
    )Net cash provided by financing activities
    
    
    
    
    
    
    
    
    
    
    20,207
    
    
    
    20,534Effect of exchange rates on cash and
cash equivalents
    
    
    
    
    
    
    
    
    
    $
    314,513
    
    
    $
    60,573
 Page 7




---



##### Table of Contents



4. Inventories Inventories are stated at the lower of cost (first-in, first-out method) or
market (net realizable value) and consist of the following: December 31, 2003
    
    March 31, 2003Raw materials
    
    $
    107,485
    
    
    $
    78,910Work-in-process
    
    
    57,499
    
    
    
    163,989Finished goods
    
    
    334,304
    
    
    
    212,215$
    499,288
    
    
    $
    455,114
 5. Comprehensive Income (Loss) Comprehensive income (loss) consists of net income (loss), and the translation
adjustment as follows: Three Months Ended
    
    Nine Months EndedDecember 31,
    
    December 31,2003
    
    2002
    
    2003
    
    2002(restated)
    
    
    
    
    
    (restated)Net income (loss)
    
    $
    (500,125
    )
    
    $
    (13,921
    )
    
    $
    (1,427,344
    )
    
    $
    319,317Items of other comprehensive
income (loss):Translation adjustment
    
    
    183,201
    
    
    
    620
    
    
    
    320,590
    
    
    
    (82,748
    )Additional pension liability
    
    
    (4,294
    )
    
    
    
    
    
    
    (7,709
    )
    
    
    Comprehensive income (loss)
    
    $
    (321,218
    )
    
    $
    (13,301
    )
    
    $
    (1,114,463
    )
    
    $
    236,569
 6. Reconciliation of Net Income (Loss) and Share Amounts Used in EPS
Calculation Basic income (loss) per common share is calculated by dividing net income
(loss) by the weighted-average common shares outstanding during the period.
Diluted income (loss) per common share for the three and nine-months ended
December 31, 2003 and 2002 was calculated using the treasury-stock method to
compute the weighted average common stock outstanding assuming the conversion
of dilutive potential common shares. Basic Income
    
    Effect of
    
    Diluted Income(Loss)
    
    Dilutive
    
    (Loss)Per Share
    
    Securities
    
    Per Share(restated)
    
    
    
    
    
    (restated)For the three months ended:December 31, 2003Net loss
    
    $
    (500,125
    )
    
    
    
    
    
    $
    (500,125
    )Shares
    
    
    4,530,657
    
    
    
    
    
    
    
    4,530,657Per share amount
    
    $
    (0.11
    )
    
    
    
    
    
    $
    (0.11
    )For the three months ended:December 31, 2002Net loss
    
    $
    (13,921
    )
    
    
    
    
    
    $
    (13,921
    )Shares
    
    
    4,467,547
    
    
    
    
    
    
    
    4,467,547Per share amount
    
    $
    (0.00
    )
    
    
    
    
    
    $
    (0.00
    )For the nine months ended:December 31, 2003Net loss
    
    $
    (1,427,344
    )
    
    
    
    
    
    $
    (1,427,344
    )Shares
    
    
    4,500,677
    
    
    
    
    
    
    
    4,500,677Per share amount
    
    $
    (0.32
    )
    
    
    
    
    
    $
    (0.32
    )For the nine months ended:December 31, 2002Net income
    
    $
    319,317
    
    
    
    
    
    
    $
    319,317Shares
    
    
    3,564,155
    
    
    
    23,841
    
    
    
    3,587,996Per share amount
    
    $
    0.09
    
    
    
    
    
    
    $
    0.09
 Page 8




---



##### Table of Contents



The following options and warrants outstanding at December 31, 2003 and 2002 to
purchase shares of common stock were excluded from diluted loss per share,
because of the anti-dilutive effect: Number of
    
    Range of ExerciseOptions/Warrants
    
    PricesFor the three months ended:December 31, 2003
    
    
    1,752,264
    
    
    $0.90 to $10.50December 31, 2002
    
    
    1,705,123
    
    
    $0.90 to $10.50For the nine months ended:December 31, 2003
    
    
    1,752,264
    
    
    $0.90 to $10.50December 31, 2002
    
    
    1,261,623
    
    
    $1.50 to $10.50
 7. Shareholders Equity The Company applies the intrinsic-value method to account for employee
stock-based compensation. As such, compensation expense, if any, is recorded on
the date of grant if the current market price of the underlying stock exceeds
the exercise price. The Company accounts for stock-based instruments granted to non-employees under
the fair value method of SFAS No. 123 and Emerging Issues Task Force (EITF)
96-18, Accounting for Equity Instruments That Are Issued to Other Than
Employees for Acquiring, or in Conjunction with Selling, Goods or Services.
Under SFAS No. 123, options are recorded at their fair value on the measurement
date, which is typically the vesting date. Consulting Agreements On April 1, 2003, the Company executed a consulting agreement with CCRI
Corporation (CCRI) to provide investor relations and development services. The
Company pays the Consultant a monthly fee of $4,000 plus expenses. CCRI
received 35,000 shares of fully vested restricted common stock, and vested
warrants to purchase 50,000 shares of common stock at an exercise price of
$3.00 per share, and received vested warrants to purchase 50,000 shares of
common stock at an exercise price of $5.00 per share on November 2, 2003. The
Company recorded the fair value of the common stock and the warrants
aggregating $212,974, as of April 1, 2003, as deferred compensation in
shareholders equity. The balance is amortized over the 1-year service period.
Also, the Company recorded the fair value of the additional warrants to acquire
50,000 of common stock aggregating $144,200, as of November 2, 2003, as
deferred compensation in shareholders equity. This balance is amortized over
the remaining 5 months of the 1-year service period. Stock-based compensation
expense for CCRI agreement for the three and nine-months ended December 31,
2003 aggregated $110,924 and $217,410, respectively. Page 9




---



##### Table of Contents



On April 1, 2003, the Company executed a consulting agreement with Executive
Advisory Group (EAG) to perform services for and on behalf of the Company. Mr.
Sam B. Humphries, a Director of the Company, is President of EAG. The Company
pays EAG a monthly fee of $6,000 plus expenses. EAG also received stock options
to purchase 50,000 shares of common stock, exercisable at $2.80 per share. The
Company recorded the fair value of the stock options aggregating $115,839, as
of April 1, 2003, as a deferred compensation in shareholders equity. The
balance is amortized over the 1-year service period. Stock-based compensation
expense for the EAG agreement for the three and nine-months ended December 31,
2003 aggregated $28,959 and $86,880, respectively. The options and warrants issued to EAG and CCRI to acquire an aggregate of
150,000 shares of common stock were fully vested upon issuance. The fair value
of these instruments was determined using the Black-Scholes options pricing
model with the following variables: April 1, 2003
    
    November 2, 2003Expected dividend yield
    
    
    0.00
    %
    
    
    0.00
    %Risk-free interest rate
    
    
    2.93
    %
    
    
    3.29
    %Expected volatility
    
    
    118
    %
    
    
    113
    %Expected life, in years
    
    
    5.00
    
    
    
    5.00
 Stock Option Grant On April 15, 2003, the Company granted 30,000 options to its Director Sam B.
Humphries, for his services as a member of the board of directors. These
options vest over a period of five years. All vesting of these options would
accelerate when the Company receives written FDA market approval or in case a
change in control should occur. Vendor Deposit In September 2001, the Company executed an agreement with a vendor to
manufacture a mold for one of the Companys products. As consideration, the
Company issued to the vendor 20,000 shares of its common stock in September
2001. The Company amended the agreement in September 2002 and issued an
additional 20,000 shares of common stock to be held in escrow until completion
of the mold. On November 3, 2003, the Company has accepted the mold and
recorded the fair value of the vested common stock aggregating $170,000 as an
addition to property, plant and equipment. 8. Stock Option Plans Had the Company determined compensation cost based on the fair value at the
grant date for its stock options under SFAS 123, Accounting for Stock-Based
Compensation, the Companys net income (loss) would have decreased (increased)
to the pro forma amounts shown below: Three Months Ended
    
    Nine Months EndedDecember 31,
    
    December 31,2003
    
    2002
    
    2003
    
    2002(restated)
    
    
    
    
    
    (restated)Net income (loss) - As reported
    
    $
    (500,125
    )
    
    $
    (13,921
    )
    
    $
    (1,427,344
    )
    
    $
    319,317Deduct: Total stock-based
employee compensation expense
determined under fair value
based method for all awards
    
    
    (43,868
    )
    
    
    (100,283
    )
    
    
    (217,367
    )
    
    
    (270,169
    )Net income (loss) - Pro forma
    
    $
    (543,993
    )
    
    $
    (114,204
    )
    
    $
    (1,644,711
    )
    
    $
    49,148Net income (loss) per common
share  As reported:Basic
    
    $
    (0.11
    )
    
    $
    (0.00
    )
    
    $
    (0.32
    )
    
    $
    0.09Diluted
    
    $
    (0.11
    )
    
    $
    (0.00
    )
    
    $
    (0.32
    )
    
    $
    0.09Net income (loss) per common
share  Pro forma:Basic
    
    $
    (0.12
    )
    
    $
    (0.03
    )
    
    $
    (0.37
    )
    
    $
    0.01Diluted
    
    $
    (0.12
    )
    
    $
    (0.03
    )
    
    $
    (0.37
    )
    
    $
    0.01
 Page 10




---



##### Table of Contents



9. Foreign Currency Gains (Losses) For the three-month periods ended December 31, 2003 and 2002, the Company
recognized foreign currency gains of $11,697 and $146,024, respectively. For
the nine-month periods ended December 31, 2003 and 2002, the Company recognized
foreign currency gains of $5,126 and $553,357, respectively. At December 31,
2003 and 2002, the Company had $0.3 million and $2.5 million of dollar
denominated intercompany debt at its Dutch subsidiaries. In January 2003, the
Company recapitalized one of the Dutch subsidiaries with an investment of 1.5
million euros ($1.6 million). The proceeds from the investment were used to
reduce the dollar denominated intercompany debt at the Dutch subsidiary.
Furthermore, the Dutch subsidiaries were profitable and the generated cash
flows were used to pay off the intercompany debt. These intercompany balances
are revolving in nature and are not deemed to be long-term balances. 10. Income Tax Expense During the quarter ended December 31, 2003, the Companys Dutch subsidiaries
recorded income tax expense of $120,914 as they have fully utilized their net
operating loss carryforwards. During the nine months ended December 31, 2003,
the Companys Dutch subsidiaries recorded income tax expense of $241,309. The
U.S. net operating loss carryforwards cannot be used to offset taxable income
in foreign jurisdictions. 11. Business Segment Information The Company sells Macroplastique and the related ancillary products for use in
augmenting soft tissues for the purpose of treating urinary incontinence and
vesicoureteral reflux. At this time, sales are only made outside the United
States because the Company has not yet made submissions to the FDA for
regulatory approval to market its products in the United States. The Companys
current objectives are to focus on sales and marketing activities designed to
increase market penetration and sales of Macroplastique for SUI, VUR, and of
PTQ Implants in countries outside the U.S., and to efficiently and effectively
execute the Macroplastique human clinical study for treatment of female SUI
within the U.S. The Company also sells injectable implant products outside the
United States for soft-tissue augmentation for specific indications in
otolaryngology and plastic surgery applications under the name Bioplastique in
limited markets. In addition, the Company sells specialized wound care products
in The Netherlands and United Kingdom as a distributor. The Macroplastique
product line accounts for 84% to 87% of total net sales during the periods
presented. Based upon the above, the Company has identified one reportable operating
segment consisting of medical products primarily for the urology market. Information regarding operations in different geographies for the three and
nine-months ended December 31, 2003 and 2002 is as follows: Page 11




---



##### Table of Contents



AdjustmentsUnited
    
    The
    
    United
    
    andStates
    
    Netherlands
    
    Kingdom
    
    Eliminations
    
    ConsolidatedFiscal 2004(restated)Sales to customers,
three-months ended 
December 31, 2003
    
    $
    
    
    
    $
    1,317,858
    
    
    $
    391,180
    
    
    $
    (261,367
    )
    
    $
    1,447,671Sales to customers,
nine-months ended 
December 31, 2003
    
    
    
    
    
    
    3,586,988
    
    
    
    1,085,354
    
    
    
    (690,009
    )
    
    
    3,982,333Income tax expense,
three-months ended 
December 31, 2003
    
    
    
    
    
    
    120,914
    
    
    
    
    
    
    
    
    
    
    
    120,914Income tax expense,
nine-months ended 
December 31, 2003
    
    
    
    
    
    
    241,309
    
    
    
    
    
    
    
    
    
    
    
    241,309Net income (loss),
three-months ended 
December 31, 2003
    
    
    (500,277
    )
    
    
    224,701
    
    
    
    (119,116
    )
    
    
    (105,433
    )
    
    
    (500,125
    )Net income (loss),
nine-months ended 
December 31, 2003
    
    
    (1,308,535
    )
    
    
    466,079
    
    
    
    (358,445
    )
    
    
    (226,443
    )
    
    
    (1,427,344
    )Long-lived assets
At December 31, 2003
    
    
    317,196
    
    
    
    786,180
    
    
    
    21,719
    
    
    
    
    
    
    
    1,125,095Fiscal 2003Sales to customers,
three-months ended 
December 31, 2002
    
    $
    
    
    
    $
    1,092,721
    
    
    $
    366,274
    
    
    $
    (194,253
    )
    
    $
    1,264,742Sales to customers,
nine-months ended
December 31, 2002
    
    
    
    
    
    
    3,366,401
    
    
    
    1,297,844
    
    
    
    (801,529
    )
    
    
    3,862,716Income tax expense,
three-months ended 
December 31, 2002
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    Income tax expense,
nine-months ended
December 31, 2002
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    Net income (loss),
three-months ended
December 31, 2002
    
    
    (563,990
    )
    
    
    457,623
    
    
    
    (53,047
    )
    
    
    145,493
    
    
    
    (13,921
    )Net income (loss),
nine-months ended 
December 31, 2002
    
    
    (1,071,362
    )
    
    
    1,246,002
    
    
    
    (18,059
    )
    
    
    162,736
    
    
    
    319,317Long-lived assets
At December 31, 2002
    
    
    103,945
    
    
    
    698,508
    
    
    
    26,977
    
    
    
    
    
    
    
    829,430
 
 ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OR PLAN OF OPERATION This Report on Form 10-QSB should be read in conjunction with the Annual Report
on Form 10-KSB for the year ended March 31, 2003. Forward-looking Statements The Registrant may from time to time make written or oral forward-looking
statements, including statements contained in this filing by the Company with
the Securities and Exchange Commission and in its reports to stockholders, as
well as elsewhere. Forward-looking statements are statements such as those
contained in projections, plans, objectives, estimates, statements of future
economic performance, and assumptions related to any of the foregoing, and may
be identified by the use of forward-looking terminology, such as may,
expect, anticipate, estimate, goal, continue, or other comparable
terminology. By their very nature, forward-looking statements are subject to
known and unknown risks and uncertainties relating to the Companys future
performance that may cause the actual results, performance, or achievements of
the Company, or industry results, to differ materially from those expressed or
implied in any such forward-looking statements. Any such statement is
qualified by reference to the following cautionary statements. Page 12




---



##### Table of Contents



The Registrants business operates in highly competitive markets and is subject
to changes in general economic conditions, competition, customer and market
preferences, government regulation, the impact of tax regulation, foreign
exchange rate fluctuations, the degree of market acceptance of products, the
uncertainties of potential litigation, as well as other risks and uncertainties
detailed elsewhere herein and from time to time in the Registrants Securities
and Exchange Commission filings. In this filing, the section entitled Managements Discussion and Analysis of
Financial Condition and Results of Operations contains forward-looking
statements. Various factors and risks (not all of which are identifiable at
this time) could cause the Companys results, performance, or achievements to
differ materially from that contained in the Companys forward-looking
statements, and investors are cautioned that any forward-looking statement
contained herein or elsewhere is qualified by and subject to the warnings and
cautionary statements contained above and in the Companys other filings with
the Securities and Exchange Commission. The Company does not undertake and assumes no obligation to update any
forward-looking statement that may be made from time to time by or on behalf of
the Company. Overview Uroplasty, Inc. develops, manufactures, and/or markets medical products in
certain segments of the urology, gynecology, urogynecology, colon and rectal,
wound care, otolaryngology and plastic surgery markets. Products sold by the
Company are subject to regulation by the U.S. FDA and/or various regulating
agencies in countries outside the U.S. Existing sales have been, and future
sales growth is expected to be, derived from Macroplastique and related
ancillary products designed for use by urologists, gynecologists, and
uro-gynecologists for the treatment of stress urinary incontinence (SUI) and
for the treatment of vesicoureteral reflux (VUR), a condition in which urine
flows backward from the bladder to the kidney. Macroplastique is comprised of
soft, irregularly textured, vulcanized, medical grade silicone elastomer
implants suspended in a biocompatible carrier solution. When injected via a
minimally invasive procedure in the soft tissue of the mid-urethra and bladder
neck (in the case of SUI), and at the ureteral orifice (in the case of
vesicoureteral reflux), the implants act as a bulking material to restore
urinary continence or to eliminate reflux of urine from the bladder to the
kidneys. In addition to the urological applications, the Companys implantable tissue
bulking material is also marketed by the Company outside the U.S. for
reconstructive and cosmetic plastic surgery applications under the trade name
Bioplastique Implants; fecal incontinence applications under the trade name
PTP Implants; and vocal cord rehabilitation under the trade name VOX
Implants. In The Netherlands and the United Kingdom, the Companys direct
sales force distributes certain wound care products on behalf of another
company in accordance with an executed Distributor Agreement. Under the terms
of the Distributor Agreement, the Company is not obligated to purchase any
minimum level of wound care products. The Companys products are currently sold by direct sales forces in the United
Kingdom and The Netherlands, and by a network of distributors in numerous
countries outside the U.S., including Western Europe, Australia, Canada and
Central and South America. The Company is currently conducting a multi-center
human clinical trial with its urethral bulking agent, Macroplastique, pursuant
to an FDA IDE as a minimally invasive, office-based procedure for treating
female SUI. This study is required as part of a Premarket Approval Submission
to the FDA for marketing within the United States. The Companys objectives are to focus on sales and marketing activities
designed to increase market penetration and sales of Macroplastique for SUI,
VUR, and of PTP Implants for fecal incontinence applications in countries
outside the U.S., and to efficiently and effectively execute the Macroplastique
clinical study for treatment of female SUI within the U.S. Critical Accounting Policies The consolidated financial statements are prepared in accordance with
accounting principles generally accepted in the United States of America, which
require the Company to make estimates and assumptions in certain circumstances
that affect amounts reported. In preparing these financial statements,
management has made its best estimates and judgments of certain amounts, giving
due consideration to materiality. The Company believes that of its significant
accounting policies, the following are particularly important to the portrayal
of the Companys results of operations and financial position and may require
the application of a higher level of judgment by the Companys management, and
as a result are subject to an inherent degree of uncertainty. Page 13




---



##### Table of Contents



Revenue Recognition and Accounts Receivable. The level of the Companys revenue
during any period is not necessarily indicative of its distributors sales to
end-user customers during that period, which are estimated not to be
substantially different than the Companys sales to those distributors in each
of the last two years. The Companys future revenue growth may be impacted by
its distributors level of inventories of the Companys products, their sales
to end-user customers and their internal product requirements. Inventories. Slow moving and obsolete inventories are valued at the lower of
cost or market based upon current and expected future product sales and the
expected impact of product transitions or modifications. In addition, the lack
of sales demand may cause our finished goods inventory to pass its use-by date
which is generally two years. The Company manufacturing production from quarter
to quarter fluctuates materially due to changes in product demand. Changes in
production significantly impact manufacturing variances. Foreign Currency Translation/Transactions. Foreign currency transaction gains
and losses are recognized currently in the statement of operations, including
unrealized gains and losses on short-term inter-company obligations using
period-end exchange rates, resulting in an increase in the volatility of the
Companys Statements of Operations. Unrealized gains and losses on long-term
inter-company obligations are recognized within accumulated other comprehensive
loss, a separate component of shareholders equity. Impairment of Long-Lived Assets. The recoverability of assets to be held and
used is measured by a comparison of the carrying amount of an asset to future
undiscounted net cash flows expected to be generated by the asset, which is
subject to considerable judgment. Set forth below is managements discussion and analysis of the financial
condition and results of operations for the three and nine-months periods ended
December 31, 2003 and 2002. Results of Operations Net Sales: In the third quarter ended December 31, 2003, net sales of all
products were $1,447,671, representing a $182,929 or 14% increase when compared
to net sales of $1,264,742 for the third quarter ended December 31, 2002.
During the nine months ended December 31, 2003, net sales of all products were
$3,982,333, representing a $119,617 or 3% increase when compared to net sales
of $3,862,716 during the nine months ended December 31, 2002. The sales
increase is the result of favorable fluctuations in foreign currency exchange
rates between the U.S. Dollar (the functional reporting currency) and the Euro
and the British Pound (currencies of the Companys subsidiaries). Excluding the
fluctuations in foreign currency exchange rates, there was a sales decrease of
approximately 1% for the three months ended December 31, 2003 and approximately
11% for the nine months ended. Management believes the decrease in sales is
related to increased competition and healthcare reform in many European
countries with procedures being limited or rationed through reimbursement
systems designed to decrease overall costs to the various national healthcare
systems. Management believes sales will increase going forward with targeted
marketing programs. The Macroplastique product line accounts for 84% to 87% of
total net sales during the periods presented. Gross Profit: Gross profit was $1,043,541 and $934,727 for the quarter ended
December 31, 2003 and 2002, respectively, or 72% and 74% of net sales. Gross
profit was $2,875,228 and $2,757,698 for the nine months ended December 31,
2003 and 2002, respectively, or 72% and 71% of net sales. Gross profit in any
one period is highly variable depending on unit sales and utilization of
manufacturing capacity. Historically, the gross margin percentage has moved
between approximately 70-80% of net sales. General and Administrative Expense: General and administrative (G&A) expenses
increased from $312,003 during the third quarter of fiscal 2003 to $493,905
during the third quarter of fiscal 2004 and increased from $884,131 during the
nine months ended December 31, 2002 to $1,450,447 during the nine months ended
December 31, 2003. Increased foreign retirement costs, consulting, legal, and
shareholder expenses, combined with general price increases and fluctuations in
foreign currency exchange rates caused the increase in G&A expenses. The
consulting fees and shareholder expenses relate to the consulting agreements
with the Executive Advisory Group (EAG) to perform services for and on behalf
of the Company and the consulting agreement with C.C.R.I. Corporation to
provide investor relations and development services. The two agreements
accounted for $169,883 and $402,290, respectively, of the increased expense for
the three and nine months ended December 31, 2003. Research and Development Expense: Research and development (R&D) expenses
decreased $83,946, or 16%, from $538,295 during the third quarter of fiscal
2003 to $454,349 during the third quarter of fiscal 2004 and decreased 13% from Page 14




---



##### Table of Contents



$1,539,503 during the nine months ended December 31, 2002 to $1,336,313 during
the nine months ended December 31, 2003. The decrease in R&D expense resulted
from a decrease in clinical costs due to the February 2003 completion of the
patient enrollment phase in the Companys multi-center IDE clinical trial. Selling and Marketing Expenses: Selling and marketing (S&M) costs increased
94% from $251,051 during the third quarter of fiscal 2003 to $487,619 during
the third quarter of fiscal 2004 and increased 68% from $764,878 during the
nine months ended December 31, 2002 to $1,286,922 during the nine months ended
December 31, 2003. The increase resulted from recruitment fees, staffing, and
dismissal payments, travel costs and costs relating to trade-shows, conventions
and congresses, marketing materials, general price increases, and fluctuations
in foreign currency exchange rates. In October and December, changes were made
in sales management resulting in termination expenses and payments in the third
quarter of fiscal 2004 of $105,000. Other Income (Expense): Other income (expense) includes interest income,
interest expense, foreign currency exchange gains and losses, settlement income
and other non-operating costs when incurred. The Companys financial results
are subject to material fluctuations based on changes in currency exchange
rates. Other income was $13,121 and $152,701 for the third quarter ended
December 31, 2003 and 2002, respectively, and $12,419 and $750,131 for the nine
months ended December 31, 2003 and 2002, respectively. The majority of the
differences between periods were due to foreign currency exchange gains and
losses and the settlement proceeds from the litigation. Exchange gains and
losses are recognized primarily as a result of fluctuations in currency rates
between the U.S. Dollar (the functional reporting currency) and the Euro and
British Pound (currencies of the Companys subsidiaries), as well as their
effect on the dollar denominated intercompany obligations between the Company
and its foreign subsidiaries. At December 31, 2003 and 2002, the Company had
$0.3 million and $2.5 million dollar denominated intercompany debt at its
foreign Dutch subsidiary. These intercompany balances are revolving in nature
and are not deemed to be long-term balances. The Company recognized foreign
currency gains of $11,697 and $146,024 for the third quarter ended December 31,
2003 and 2002, respectively, and $5,126 and $553,357 for the nine months ended
December 31, 2003 and 2002, respectively. The currency gains are primarily the
result of a weakened U.S. Dollar compared to the Euro. In January 2003, the
Company recapitalized one of the Dutch subsidiaries with an investment of 1.5
million Euros ($1.6 million). The Company used proceeds from the investment to
reduce the dollar denominated intercompany debt at the Dutch subsidiary,
resulting in an adjusted balance at December 31, 2002 of $0.9 million of
intercompany debt at the Dutch subsidiary subject for foreign currency
transaction accounting. This resulted in less volatility for changes in
currency exchange rates in the Companys statement of operations. Income Tax Expense: During the quarter ended December 31, 2003, the Companys
Dutch subsidiaries recorded income tax expense of $120,914 as they have fully
utilized their net operating loss carryforwards. During the nine-months ended
December 31, 2003, the Companys Dutch subsidiaries recorded income tax expense
of $241,309. The U.S. net operating loss carryforwards cannot be used to offset
taxable income in foreign jurisdictions. Management expects continued profits
for its Dutch subsidiaries and therefore continued income tax expenses. The
Dutch income tax rate is 29% for euro 22,689 of profit and 34.5% for the amount
above euro 22,689 Liquidity and Capital Resources As of December 31, 2003, the Companys cash and cash equivalent balances
totaled $2,613,903. At December 31, 2003, the Company had working capital of approximately $3.6
million. During the nine months ended December 31, 2003, $760,743 of cash was
used in operating activities, compared to $482,491 of cash provided by
operating activities in the prior-year period. The usage of cash was primarily
attributable to the net loss incurred of $1,427,344, compared to a profit of
$319,317 in the prior year period. Accounts receivable decreased by $84,563,
compared to a decrease of $44,905 for the prior-year period, due to the timing
of payment by our customers. Other current assets, accounts payable and accrued
expenses fluctuated due to the timing of payments and fluctuations in foreign
currency exchange rates. The Company recorded $304,290 of non-cash stock-based
compensation expense during the nine-months ended December 31, 2003, compared
to $1,508 for the prior-year period. This increase was due to the stock-based
investor relations and other consulting agreements the Company consummated on
April 1, 2003 with C.C.C.R. Corporation and Executive Advisory Group. Net cash
used in investing activities for the nine months ended December 31, 2003 is
$82,442, compared to net cash used of $45,432 for the prior-year period. The
increase was due to computer hardware and software expenditures and
expenditures for obtaining patent rights. Net cash provided by financing
activities for the nine months ended December 31, 2003 is $20,534, compared to
net cash provided by financing activities of $2,227,642. This results from
repayment of long-term debt and net proceeds from issuance of stock. In July
2002, the Company completed its rights offering to its shareholders. Page 15




---



##### Table of Contents



The Company currently has no financing arrangements in place with any bank for
general working capital needs, and no material unused sources of liquidity
other than the cash, equipment leasing arrangements, and its accounts
receivable and inventory balances at December 31, 2003 of $1,021,959 and
$499,288, respectively. For fiscal 2004, management does not anticipate any
material capital expenditures. The Companys financial condition and results of operations could be materially
affected by fluctuations in foreign currency exchange rates and weak economic
conditions in foreign markets where the Companys products are distributed.
The effects of these conditions could include reduced unit sales and reduced
sales in dollars when converted from foreign currency amounts and material
gains and losses on transactions denominated in foreign currencies.
Furthermore, because the Companys U.S. operations are funded by sales
denominated in foreign currency, strengthening of the U.S. dollar against the
Euro, and/or the British Pound could have an adverse effect on the Companys
cash flow and results of operations. Management expects continued high costs associated with the conduct of the U.S.
human clinical study for Macroplastique pursuant to the FDA approved IDE, the
subsequent U.S. Premarket Approval process, and pre-commercialization and
market launch costs in the U.S. relating to Macroplastique for female SUI. Management believes that current resources and the funds generated from sale of
the Companys products outside the U.S. will be adequate to meet the Companys
cash flow needs, including R&D activities associated with existing products and
markets through fiscal 2005. Ultimately, the Company will need to achieve
profitability and positive cash flows from operations or obtain additional debt
or equity financing to fund its operations. 
 ITEM 3. CONTROLS AND PROCEDURES. Disclosure Controls and Procedures. Within the 90 days prior to the date of
this report, Daniel G. Holman, our President, Chief Executive Officer, Chief
Financial Officer and Arie J. Koole, our Controller, Principal Accounting
Officer, carried out an evaluation of the effectiveness of the design and
operation of our disclosure controls and procedures pursuant to Rule 13a-15b
under the Securities Exchange Act of 1934. Based on their review of our
disclosure controls and procedures, such officers have concluded that our
disclosure controls and procedures are effective in timely alerting them to
material information relating to us that is required to be included in our
periodic SEC filings. Internal Controls and Procedures. There were no significant changes in
internal controls or in other factors that could significantly affect these
controls subsequent to the date of their evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses. Page 16




---



##### Table of Contents



PART II. OTHER INFORMATION Except as indicated below, none of the items contained in PART II of Form
10-QSB are applicable to the Company for the three months ended December 31,
2003. 
 ITEM 2. CHANGES IN SECURITIES ( c ) Recent Sales of Unregistered Securities None. 
 ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K. (a) Exhibits 31 Certifications by the Chief Executive Officer/Chief Financial Officer and
the Controller pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32 Certifications by the Chief Executive Officer/Chief Financial Officer and
the Controller pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (this
Exhibit is furnished pursuant to SEC rules, but is deemed not filed) 99.1 Press release dated February 12, 2004 (Previously Filed) (b) Reports on Form 8-K None Page 17




---



##### Table of Contents



SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized. UROPLASTY, INC. Date: November 17, 2004
    
    by: /s/ DANIEL G. HOLMANDaniel G. HolmanPresident, Chief Executive Officer,Chief Financial Officer and Director (Principal Executiveand Financial Officer)Date: November 17, 2004
    
    by: /s/ ARIE J. KOOLEArie J. KooleController (Principal Accounting Officer)
 Page 18